Pharma Focus Asia

OBI-992 Secures FDA Approval to Commence Phase I/II Clinical Trials

Thursday, January 04, 2024

Taiwan's Halogen Biotech (4174.TWO) has announced the independent development of a new antibody-drug complex (ADC) drug, OBI-992, targeting TROP2. The U.S. Food and Drug Administration (FDA) has granted approval for a Phase I/II clinical trial to evaluate its safety and efficacy.

OBI-992's clinical trial aims to treat patients with advanced solid tumors, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer (GC), and other potential targets. Dr. Wayne Saville, MD, Chief Medical Officer of Taiwan Haoding, highlighted the trial's purpose of assessing the safety, pharmacokinetics, and preliminary efficacy of OBI-992, expressing belief in its potential as a leading-class drug. Phase I/II trials for TROP2 ADC are set to begin in early 2024, with the first patient scheduled to be dosed.

Dr. Wang Huijun, CEO of Taiwan's Haoding, explained that OBI-992 is a new TROP2 ADC designed and produced in-house, demonstrating superior efficacy and safety in preclinical trials compared to other TROP2 ADCs. Dr. Huijun expressed excitement about OBI-992 entering human clinical trials for the first time, emphasizing Haoding's commitment to advancing potential cancer therapies into the clinic promptly.

OBI-992, an Antibody Drug Conjugate (ADC), is designed to target TROP2, highly expressed in various solid tumors. It utilizes a hydrophilic linker to connect antibodies and potent TOP1 (topoisomerase I) inhibitors, ensuring stability in the bloodstream. Once bound to TROP2 on cancer cell surfaces, OBI-992 releases small molecule drugs internally to induce cell death. Preclinical studies with animal models have demonstrated OBI-992's effective anti-tumor activity, favorable pharmacokinetics, and safety.

The TROP2 antibody, introduced by Taiwan's Haoding Biotechnology in December 2021 with authorization from Boaoxin Company, is part of Haoding's responsibility for ADC construction, research and development, and commercialization rights outside of China.

 

Source: globenewswire.com

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024